Skip to content

The study of pharmacists on the management of lipids with very-high-risk coronary atherosclerotic cardiovascular disease patients

The study of pharmacists on the management of lipids with very-high-risk coronary atherosclerotic cardiovascular disease patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045012
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic cardiovascular disease

Interventions

Pharmacist Intervention Group:Pharmacist management path+Routine education

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Sign the informed consent; 2.Age 18-80 years old, no gender limit; 3.Diagnosed with coronary atherosclerosis and cardiovascular disease, coexisting one of the following conditions: 1) Two or more episodes of ACS within two years 2) Multivessel coronary artery disease (two or more main coronary arteries stenosis more than 50%) 3) Recent ACS (within 1 year) 4) Heart, brain or peripheral multivascular bed atherosclerotic vascular disease 5) LDL-C >= 4.9 mmol/L (190 mg/dl) 6) Diabetes 4. Can be contacted by phone, willing to cooperate with the pharmacist for follow-up.

Exclusion criteria

Exclusion criteria: 1. Mental disorders, unable to communicate normally; 2. There are serious/severe coexisting diseases whose life expectancy may be less than 6 months; 3. Pregnant or lactating women; 4. In patients with severe renal insufficiency, the clearance rate of endogenous creatinine is less than 30 ml/min; 5. Active liver disease or liver dysfunction, ALT is greater than 3 times the normal value and/or total bilirubin is greater than 2 times; 6. New York Heart Association (NYHA) grade IV heart failure; 7. Patients who participated in other clinical trials in the past 3 months; 8. Non-cooperative persons (who cannot cooperate with diet control, or those who do not follow the prescribed medication and affect the curative effect); 9. Other reasons that the researcher thinks are not suitable for this study.

Design outcomes

Primary

MeasureTime frame
Low-density lipoprotein;

Secondary

MeasureTime frame
Total cholesterol;Morisky-8 scale evaluation results;Disease and drug cognition;EuroQol-5 Dimensions (EQ-5D);

Countries

China

Contacts

Public ContactHuang Ping

Zhejiang Provincial People's Hospital

tdyyyjk@126.com+86 13858072398

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026